english.prescrire.org > Prescrire International > N°219 - October 2020

n°219

October 2020

Issue Contents
Editorial

Free  Hydroxychloroquine: the situation is critical

p.227

New Products


Ibalizumab (Trogarzo°) in multidrug-resistant HIV infection

p.229-232
A possible option when no optimised antiretroviral regimens are effective

Inset. Pharmacological classes of the main anti­retroviral drugs

p.231

Olaparib tablets (Lynparza°) as maintenance therapy for ovarian cancer after first-line chemotherapy

p.232-233

Olaparib (Lynparza°) and certain inoperable breast cancers with BRCA mutation

p.233

Dolutegravir + lamivudine (Dovato°) and HIV infection

p.234-237
A two-drug regimen to be considered on a case-by-case basis

INN Common stem: -tegravir

p.235

Editors' opinion. Simplification?

p.236

INN Common stem: gab-, -gab-

p.237

Adverse Effects


Apixaban, edoxaban, rivaroxaban: situations with a high risk of bleeding or thrombosis

p.238-241

Efavirenz and pregnancy: microcephaly and neural tube defects

p.242

Gentian violet when breastfeeding: irritant and carcinogenic

p.243

In utero exposure to DES: a risk factor for myocardial infarction?

p.244

Cetirizine: dystonia and other extrapyramidal disorders

p.245-246

Tocilizumab: severe liver injury

p.246

Reviews


Pinworm infection

p.247-248
Often easy to treat

Head injury and intracranial bleeding

p.248
Tranexamic acid can be useful

Outlook


European clinical trials register: too few results reported

p.249

Free  A public awareness campaign which mainly benefits companies

p.250

Clinical trials: primary outcome measures 
often modified

p.251

Opioids: WHO recommendations influenced by pharmaceutical companies

p.251

Masthead


Free  Masthead

p.226

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe